Arthur McGivern
Vermögen: 40 Mio $ am 31.05.2026
Vermögen: 40 Mio $ am 31.05.2026
Arthur R.
McGivern is currently Outside General Counsel at Guide Medical Ventures LLC and Executive VP-Investments & General Counsel at Royalty Pharma Plc since 2022.
Formerly, Mr. McGivern was a Corporate Officer at Goodwin Procter LLP from 2005 to 2010.
Mr. McGivern completed undergraduate studies at Tufts University in 1997 and graduate studies at Boston University School of Law in 2004.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROYALTY PHARMA PLC 2,88 % | 06.04.2026 | 706.393 ( 2,88 % ) | 39 Mio $ | 31.05.2026 |
| 06.04.2026 | 3.668 ( 0 % ) | 204 528 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ROYALTY PHARMA PLC | Chief Investment Officer | 12.10.2022 |
Guide Medical Ventures LLC
Guide Medical Ventures LLC Medical/Nursing ServicesHealth Services Develops medical devices | General Counsel | - |
| Unternehmen | Position | Ende |
|---|---|---|
Goodwin Procter LLP
Goodwin Procter LLP Investment ManagersFinance Functions as an alternative investment manager | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Goodwin Procter LLP
Goodwin Procter LLP Investment ManagersFinance Functions as an alternative investment manager | Finance |
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston University School of Law
Boston University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Guide Medical Ventures LLC
Guide Medical Ventures LLC Medical/Nursing ServicesHealth Services Develops medical devices | Health Services |
Royalty Pharma Plc
Royalty Pharma Plc Pharmaceuticals: MajorHealth Technology Buys and operates a portfolio of biopharmaceutical royalties | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen